A peptide antagonist of thrombospondin-1 promotes abdominal aortic aneurysm progression in the angiotensin II-infused apolipoprotein-E-deficient mouse

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 2, 2015, Pages 389-398

  Krishna, Smriti M ^a   Seto, Sai Wang ^a   Jose, Roby J ^a   Biros, Erik ^a   Moran, Corey S ^a   Wang, Yutang ^a   Clancy, Paula ^a   Golledge, Jonathan ^a,b  

^a JAMES COOK UNIVERSITY   (Australia)

^b TOWNSVILLE HOSPITAL   (Australia)

Author keywords

abdominal aortic aneurysm; angiotensin II; LSKL; thrombospondin 1; transforming growth factor 1

Indexed keywords

ANGIOTENSIN II; APOLIPOPROTEIN E; ELASTIN; LEUCINE SERINE LYSINE LEUCINE; PEPTIDE; SMAD2 PROTEIN; SMAD3 PROTEIN; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; AUTACOID; CYTOKINE; LEU-SER-LYS-LEU PEPTIDE; LOXL1 PROTEIN, MOUSE; OXIDOREDUCTASE; PROTEIN SERINE THREONINE KINASE; SMAD2 PROTEIN, MOUSE; SMAD3 PROTEIN, MOUSE; TGF-BETA TYPE I RECEPTOR; TGFB1 PROTEIN, MOUSE; THROMBOSPONDIN-1, MOUSE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR;

ABDOMINAL AORTA ANEURYSM; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; AORTA ARCH; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DISEASE COURSE; GENE; GENE EXPRESSION; HYPERLIPOPROTEINEMIA TYPE 3; INFLAMMATION; INFLAMMATORY CELL; LOXL1 GENE; MORPHOMETRICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TGFBR1 GENE; TGFBRII GENE; ULTRASOUND; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; GENETICS; INTRAPERITONEAL DRUG ADMINISTRATION; KNOCKOUT MOUSE; MALE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TIME;

AMINO ACID OXIDOREDUCTASES; ANGIOTENSIN II; ANIMALS; AORTA; AORTIC ANEURYSM, ABDOMINAL; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CYTOKINES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ELASTIN; INFLAMMATION MEDIATORS; INJECTIONS, INTRAPERITONEAL; MALE; MICE, KNOCKOUT; PEPTIDES; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SMAD2 PROTEIN; SMAD3 PROTEIN; THROMBOSPONDIN 1; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84922070169     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.304732     Document Type: Article

References (60)

1. Golledge J, Norman PE. Pathophysiology of abdominal aortic aneurysm relevant to improvements in patients' management. Curr Opin Cardiol. 2009;24:532-538. doi: 10.1097/HCO.0b013e328330c2d3.
2. Moxon JV, Parr A, Emeto TI, Walker P, Norman PE, Golledge J. Diagnosis and monitoring of abdominal aortic aneurysm: current status and future prospects. Curr Probl Cardiol. 2010;35:512-548. doi: 10.1016/j. cpcardiol.2010.08.004.
3. Golledge J, Muller J, Daugherty A, Norman P. Abdominal aortic aneurysm: pathogenesis and implications for management. Arterioscler Thromb Vasc Biol. 2006;26:2605-2613. doi: 10.1161/01.ATV.0000245819.32762.cb.
4. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med. 1994;331:1286-1292. doi: 10.1056/ NEJM199411103311907.
5. Biros E, Walker PJ, Nataatmadja M, West M, Golledge J. Downregulation of transforming growth factor, beta receptor 2 and Notch signaling pathway in human abdominal aortic aneurysm. Atherosclerosis. 2012;221:383-386. doi: 10.1016/j.atherosclerosis.2012.01.004.
6. Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006;312:117-121. doi: 10.1126/science.1124287.
7. Holm TM, Habashi JP, Doyle JJ, et al. Noncanonical TGFβ signaling contributes to aortic aneurysm progression in Marfan syndrome mice. Science. 2011;332:358-361. doi: 10.1126/science.1192149.
8. Gacchina C, Brothers T, Ramamurthi A. Evaluating smooth muscle cells from CaCl2-induced rat aortal expansions as a surrogate culture model for study of elastogenic induction of human aneurysmal cells. Tissue Eng Part A. 2011;17:1945-1958. doi: 10.1089/ten.TEA.2010.0475.
9. Dai J, Michineau S, Franck G, Desgranges P, Becquemin JP, Gervais M, Allaire E. Long term stabilization of expanding aortic aneurysms by a short course of cyclosporine A through transforming growth factor-beta induction. PLoS One. 2011;6:e28903. doi: 10.1371/journal. pone.0028903.
10. Dai J, Losy F, Guinault AM, Pages C, Anegon I, Desgranges P, Becquemin JP, Allaire E. Overexpression of transforming growth factor-beta1 stabilizes already-formed aortic aneurysms: a first approach to induction of functional healing by endovascular gene therapy. Circulation. 2005;112:1008-1015. doi: 10.1161/CIRCULATIONAHA.104.523357.
11. Wang Y, Ait-Oufella H, Herbin O, Bonnin P, Ramkhelawon B, Taleb S, Huang J, Offenstadt G, Combadière C, Rénia L, Johnson JL, Tharaux PL, Tedgui A, Mallat Z. TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice. J Clin Invest. 2010;120:422-432. doi: 10.1172/JCI38136.
12. Abe M, Oda N, Sato Y, Shibata K, Yamasaki M. Augmented binding and activation of latent transforming growth factor-beta by a tryptic fragment of latency associated peptide. Endothelium. 2002;9:25-36.
13. Krishna SM, Golledge J. The role of thrombospondin-1 in cardiovascular health and pathology. Int J Cardiol. 2013;168:692-706. doi: 10.1016/j. ijcard.2013.04.139.
14. Lawler J. The functions of thrombospondin-1 and-2. Curr Opin Cell Biol. 2000;12:634-640.
15. Xie XS, Li FY, Liu HC, Deng Y, Li Z, Fan JM. LSKL, a peptide antagonist of thrombospondin-1, attenuates renal interstitial fibrosis in rats with unilateral ureteral obstruction. Arch Pharm Res. 2010;33:275-284. doi: 10.1007/s12272-010-0213-6.
16. Ribeiro SM, Poczatek M, Schultz-Cherry S, Villain M, Murphy-Ullrich JE. The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-beta. J Biol Chem. 1999;274:13586-13593.
17. Belmadani S, Bernal J, Wei CC, Pallero MA, Dell'italia L, Murphy-Ullrich JE, Berecek KH. A thrombospondin-1 antagonist of transforming growth factor-beta activation blocks cardiomyopathy in rats with diabetes and elevated angiotensin II. Am J Pathol. 2007;171:777-789. doi: 10.2353/ ajpath.2007.070056.
18. Breitkopf K, Sawitza I, Westhoff JH, Wickert L, Dooley S, Gressner AM. Thrombospondin 1 acts as a strong promoter of transforming growth factor beta effects via two distinct mechanisms in hepatic stellate cells. Gut. 2005;54:673-681. doi: 10.1136/gut.2004.042911.
19. Kondou H, Mushiake S, Etani Y, Miyoshi Y, Michigami T, Ozono K. A blocking peptide for transforming growth factor-beta1 activation prevents hepatic fibrosis in vivo. J Hepatol. 2003;39:742-748.
20. Dickson MC, Martin JS, Cousins FM, Kulkarni AB, Karlsson S, Akhurst RJ. Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. Development. 1995;121:1845-1854.
21. Oshima M, Oshima H, Taketo MM. TGF-beta receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. Dev Biol. 1996;179:297-302. doi: 10.1006/dbio.1996.0259.
22. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev. 2000;14:163-176.
23. Godár S, Horejsi V, Weidle UH, Binder BR, Hansmann C, Stockinger H. M6P/IGFII-receptor complexes urokinase receptor and plasminogen for activation of transforming growth factor-beta1. Eur J Immunol. 1999;29:1004-1013. doi: 10.1002/ (SICI)1521-4141(199903)29:0360;1004::AID-IMMU10043.0. CO;2-Q.
24. Blakytny R, Ludlow A, Martin GE, Ireland G, Lund LR, Ferguson MW, Brunner G. Latent TGF-beta1 activation by platelets. J Cell Physiol. 2004;199:67-76. doi: 10.1002/jcp.10454.
25. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, Pittet JF, Kaminski N, Garat C, Matthay MA, Rifkin DB, Sheppard D. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell. 1999;96:319-328.
26. Golledge J, Norman PE. Current status of medical management for abdominal aortic aneurysm. Atherosclerosis. 2011;217:57-63. doi: 10.1016/j.atherosclerosis.2011.03.006.
27. Sethi A, Mao W, Wordinger RJ, Clark AF. Transforming growth factorbeta induces extracellular matrix protein cross-linking lysyl oxidase (LOX) genes in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2011;52:5240-5250. doi: 10.1167/iovs.11-7287.
28. Chen MM, Lam A, Abraham JA, Schreiner GF, Joly AH. CTGF expression is induced by TGF-beta in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis. J Mol Cell Cardiol. 2000;32:1805-1819. doi: 10.1006/jmcc.2000.1215.
29. Samarakoon R, Higgins PJ. Integration of non-SMAD and SMAD signaling in TGF-beta1-induced plasminogen activator inhibitor type-1 gene expression in vascular smooth muscle cells. Thromb Haemost. 2008;100:976-983.
30. Lu A, Miao M, Schoeb TR, Agarwal A, Murphy-Ullrich JE. Blockade of TSP1-dependent TGF-β activity reduces renal injury and proteinuria in a murine model of diabetic nephropathy. Am J Pathol. 2011;178:2573-2586. doi: 10.1016/j.ajpath.2011.02.039.
31. Narmada BC, Chia SM, Tucker-Kellogg L, Yu H. HGF regulates the activation of TGF-β1 in rat hepatocytes and hepatic stellate cells. J Cell Physiol. 2013;228:393-401. doi: 10.1002/jcp.24143.
32. Wang S, Lincoln TM, Murphy-Ullrich JE. Glucose downregulation of PKG-I protein mediates increased thrombospondin1-dependent TGF-{beta} activity in vascular smooth muscle cells. Am J Physiol Cell Physiol. 2010;298:C1188-C1197. doi: 10.1152/ajpcell.00330.2009.
33. Losy F, Dai J, Pages C, Ginat M, Muscatelli-Groux B, Guinault AM, Rousselle E, Smedile G, Loisance D, Becquemin JP, Allaire E. Paracrine secretion of transforming growth factor-beta1 in aneurysm healing and stabilization with endovascular smooth muscle cell therapy. J Vasc Surg. 2003;37:1301-1309.
34. King VL, Lin AY, Kristo F, Anderson TJ, Ahluwalia N, Hardy GJ, Owens AP III, Howatt DA, Shen D, Tager AM, Luster AD, Daugherty A, Gerszten RE. Interferon-gamma and the interferon-inducible chemokine CXCL10 protect against aneurysm formation and rupture. Circulation. 2009;119:426-435. doi: 10.1161/CIRCULATIONAHA.108.785949.
35. Rateri DL, Howatt DA, Moorleghen JJ, Charnigo R, Cassis LA, Daugherty A. Prolonged infusion of angiotensin II in apoE(-/-) mice promotes macrophage recruitment with continued expansion of abdominal aortic aneurysm. Am J Pathol. 2011;179:1542-1548. doi: 10.1016/j. ajpath.2011.05.049.
36. Inoue N, Muramatsu M, Jin D, Takai S, Hayashi T, Katayama H, Kitaura Y, Tamai H, Miyazaki M. Involvement of vascular angiotensin II-forming enzymes in the progression of aortic abdominal aneurysms in angiotensin II-infused ApoE-deficient mice. J Atheroscler Thromb. 2009;16:164-171.
37. Zhou Y, Chen R, Catanzaro SE, Hu L, Dansky HM, Catanzaro DF. Differential effects of angiotensin II on atherogenesis at the aortic sinus and descending aorta of apolipoprotein-E-deficient mice. Am J Hypertens. 2005;18(4 Pt 1):486-492. doi: 10.1016/j.amjhyper.2004.11.005.
38. Ayabe N, Babaev VR, Tang Y, Tanizawa T, Fogo AB, Linton MF, Ichikawa I, Fazio S, Kon V. Transiently heightened angiotensin II has distinct effects on atherosclerosis and aneurysm formation in hyperlipidemic mice. Atherosclerosis. 2006;184:312-321. doi: 10.1016/j. atherosclerosis.2005.05.016.
39. Seto SW, Krishna SM, Moran CS, Liu D, Golledge J. Aliskiren limits abdominal aortic aneurysm, ventricular hypertrophy and atherosclerosis in an apolipoprotein-E-deficient mouse model. Clin Sci (Lond). 2014;127:123-134. doi: 10.1042/CS20130382.
40. Krishna SM, Seto SW, Moxon JV, Rush C, Walker PJ, Norman PE, Golledge J. Fenofibrate increases high-density lipoprotein and sphingosine 1 phosphate concentrations limiting abdominal aortic aneurysm progression in a mouse model. Am J Pathol. 2012;181:706-718. doi: 10.1016/j.ajpath.2012.04.015.
41. Torsney E, Pirianov G, Charolidi N, Shoreim A, Gaze D, Petrova S, Laing K, Meisinger T, Xiong W, Baxter BT, Cockerill GW. Elevation of plasma high-density lipoproteins inhibits development of experimental abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2012;32:2678-2686. doi: 10.1161/ATVBAHA.112.00009.
42. Mallat Z, Gojova A, Marchiol-Fournigault C, Esposito B, Kamaté C, Merval R, Fradelizi D, Tedgui A. Inhibition of transforming growth factorbeta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res. 2001;89:930-934.
43. Robertson AK, Rudling M, Zhou X, Gorelik L, Flavell RA, Hansson GK. Disruption of TGF-beta signaling in T cells accelerates atherosclerosis. J Clin Invest. 2003;112:1342-1350. doi: 10.1172/JCI18607.
44. Golledge J, Norman PE. Atherosclerosis and abdominal aortic aneurysm: cause, response, or common risk factors? Arterioscler Thromb Vasc Biol. 2010;30:1075-1077. doi: 10.1161/ATVBAHA.110.206573.
45. Liu J, Sukhova GK, Sun JS, Xu WH, Libby P, Shi GP. Lysosomal cysteine proteases in atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24:1359-1366. doi: 10.1161/01.ATV.0000134530.27208.41.
46. Newman KM, Jean-Claude J, Li H, Ramey WG, Tilson MD. Cytokines that activate proteolysis are increased in abdominal aortic aneurysms. Circulation. 1994;90(5 Pt 2):II224-II227.
47. Thompson RW, Holmes DR, Mertens RA, Liao S, Botney MD, Mecham RP, Welgus HG, Parks WC. Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms. An elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages. J Clin Invest. 1995;96:318-326. doi: 10.1172/JCI118037.
48. Frutkin AD, Otsuka G, Stempien-Otero A, Sesti C, Du L, Jaffe M, Dichek HL, Pennington CJ, Edwards DR, Nieves-Cintrón M, Minter D, Preusch M, Hu JH, Marie JC, Dichek DA. TGF-[beta]1 limits plaque growth, stabilizes plaque structure, and prevents aortic dilation in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol. 2009;29:1251-1257. doi: 10.1161/ ATVBAHA.109.186593.
49. Rucker RB, Tinker D. Structure and metabolism of arterial elastin. Int Rev Exp Pathol. 1977;17:1-47.
50. Antoniou GA, Georgiadis GS, Antoniou SA, Granderath FA, Giannoukas AD, Lazarides MK. Abdominal aortic aneurysm and abdominal wall hernia as manifestations of a connective tissue disorder. J Vasc Surg. 2011;54:1175-1181. doi: 10.1016/j.jvs.2011.02.065.
51. Tao M, Yu P, Nguyen BT, Mizrahi B, Savion N, Kolodgie FD, Virmani R, Hao S, Ozaki CK, Schneiderman J. Locally applied leptin induces regional aortic wall degeneration preceding aneurysm formation in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2013;33:311-320. doi: 10.1161/ATVBAHA.112.300543.
52. Rizzo RJ, McCarthy WJ, Dixit SN, Lilly MP, Shively VP, Flinn WR, Yao JS. Collagen types and matrix protein content in human abdominal aortic aneurysms. J Vasc Surg. 1989;10:365-373.
53. Campa JS, Greenhalgh RM, Powell JT. Elastin degradation in abdominal aortic aneurysms. Atherosclerosis. 1987;65:13-21.
54. Guha M, Xu ZG, Tung D, Lanting L, Natarajan R. Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes. FASEB J. 2007;21:3355-3368. doi: 10.1096/fj.06-6713com.
55. Chen Y, Leask A, Abraham DJ, Pala D, Shiwen X, Khan K, Liu S, Carter DE, Wilcox-Adelman S, Goetinck P, Denton CP, Black CM, Pitsillides AA, Sarraf CE, Eastwood M. Heparan sulfate-dependent ERK activation contributes to the overexpression of fibrotic proteins and enhanced contraction by scleroderma fibroblasts. Arthritis Rheum. 2008;58:577-585. doi: 10.1002/art.23146.
56. Samarakoon R, Higgins SP, Higgins CE, Higgins PJ. TGF-beta1-induced plasminogen activator inhibitor-1 expression in vascular smooth muscle cells requires pp60(c-src)/EGFR(Y845) and Rho/ROCK signaling. J Mol Cell Cardiol. 2008;44:527-538. doi: 10.1016/j.yjmcc.2007.12.006.
57. Liu X, Zhao Y, Gao J, Pawlyk B, Starcher B, Spencer JA, Yanagisawa H, Zuo J, Li T. Elastic fiber homeostasis requires lysyl oxidase-like 1 protein. Nat Genet. 2004;36:178-182. doi: 10.1038/ng1297.
58. Sibon I, Sommer P, Lamaziere JM, Bonnet J. Lysyl oxidase deficiency: a new cause of human arterial dissection. Heart. 2005;91:e33. doi: 10.1136/ hrt.2004.053074.
59. Hornstra IK, Birge S, Starcher B, Bailey AJ, Mecham RP, Shapiro SD. Lysyl oxidase is required for vascular and diaphragmatic development in mice. J Biol Chem. 2003;278:14387-14393. doi: 10.1074/jbc. M210144200.
60. Song YL, Ford JW, Gordon D, Shanley CJ. Regulation of lysyl oxidase by interferon-gamma in rat aortic smooth muscle cells. Arterioscler Thromb Vasc Biol. 2000;20:982-988.